Showing results (3101-3110 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 21, 2017
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse eventFrancesco Gelsomino, Giovanni Vitale, Andrea Ardizzoni
Investigational New Drugs|June 21, 2017
Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cellsJoana Liberal, Anália Carmo, Célia Gomes, et al.
Investigational New Drugs|March 13, 2010
In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexesGeorgi Momekov, Margarita Karaivanova, Iva Ugrinova, et al.
Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.
Investigational New Drugs|March 6, 2010
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)José María Viéitez, Manuel Valladares, Ignacio Peláez, et al.
Investigational New Drugs|June 12, 2017
Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancerTomoyoshi Takenaka, Koji Yamazaki, Naoko Miura, et al.
Investigational New Drugs|April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisJihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.
Investigational New Drugs|February 1, 1991
A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group studyJ H Malfetano, J A Blessing, H D Homesley, et al.
Investigational New Drugs|February 1, 1991
Multipolar mitotic cells in the human cell line NHIK 3025 following treatment with the mitotic inhibitor NY 4137M E Juul, J M Dornish, P E Schwarze, et al.
Investigational New Drugs|February 1, 1991
Crisnatol mesylate: phase I dose escalation by extending infusion durationE A Poplin, G G Chabot, R L Tuttle, et al.
Pageof 372